DESTINY-Breast03 Study: Trastuzumab Deruxtecan versus Trastuzumab Emtansine

Let Giuseppe Curigliano from the European Institute of Oncology IRCCS present you patient-reported outcomes in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase 3 DESTINY-Breast03 study.